v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Operating expenses:        
Research and development $ 1,643,659 $ 744,173 $ 4,950,457 $ 3,056,101
General and administrative 3,841,189 2,405,722 14,380,898 8,492,070
Depreciation and amortization 18,510 2,977 36,424 8,806
Total operating expenses 5,503,358 3,152,872 19,367,779 11,556,977
Loss from operations (5,503,358) (3,152,872) (19,367,779) (11,556,977)
Other income (expense):        
Interest income, net 39,354 1,943 84,623 2,291
Loss before income taxes (5,464,004) (3,150,929) (19,283,156) (11,554,686)
Income taxes (benefit) 0 0 0 0
Net loss (5,464,004) (3,150,929) (19,283,156) (11,554,686)
Preferred stock dividend (4,877) (194,433) (20,286) (780,346)
Net loss attributable to common stockholders (5,468,881) (3,345,362) (19,303,442) (12,335,032)
Non-controlling interest 20,538 0 20,538 0
NET LOSS ATTRIBUTABLE TO BIOSIG TECHNOLOGIES, INC. $ (5,448,343) $ (3,345,362) $ (19,282,904) $ (12,335,032)
Net loss per common share, basic and diluted (in Dollars per share) $ (0.25) $ (0.22) $ (0.96) $ (0.89)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 21,809,998 15,529,568 20,124,322 13,784,553

Source